Acadia Pharmaceuticals Inc. (ACAD)
NASDAQ: ACAD · Real-Time Price · USD
18.75
+0.61 (3.36%)
At close: Nov 13, 2026, 4:00 PM EST
18.80
+0.05 (0.27%)
Pre-market: Nov 16, 2026, 7:00 AM EST
Acadia Pharmaceuticals Employees
As of December 31, 2025, Acadia Pharmaceuticals had 798 total employees, including 796 full-time and 2 part-time employees. The number of employees increased by 144 or 22.02% compared to the previous year. That makes Acadia Pharmaceuticals the 16,537th largest employer in the world and 2,334th in the United States.
Employees
798
Change (1Y)
144
Growth (1Y)
22.02%
Revenue / Employee
$1,506,643
Profits / Employee
$453,921
Market Cap
3.24B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 798 | 144 | 22.02% | 796 | 2 |
| Dec 31, 2024 | 654 | 56 | 9.36% | 653 | 1 |
| Dec 31, 2023 | 598 | 85 | 16.57% | 597 | 1 |
| Dec 31, 2022 | 513 | -1 | -0.19% | 511 | 2 |
| Dec 31, 2021 | 514 | -87 | -14.48% | 512 | 2 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Legend Biotech | 3,300 |
| Telix Pharmaceuticals | 1,184 |
| Iovance Biotherapeutics | 975 |
| ADMA Biologics | 647 |
| Denali Therapeutics | 507 |
| Arcutis Biotherapeutics | 354 |
| Dyne Therapeutics | 322 |
| Viridian Therapeutics | 252 |
ACAD News
- 3 days ago - Acadia Pharmaceuticals price target lowered to $24 from $28 at Morgan Stanley - TheFly
- 5 days ago - Acadia Pharmaceuticals to present Remlifanserin data at CTAD - TheFly
- 5 days ago - Acadia comments on federal court oral argument in Nuplazid patent appeal - TheFly
- 6 days ago - Acadia Pharmaceuticals Comments on Federal Circuit Oral Argument in NUPLAZID® Formulation Patent Appeal - Business Wire
- 6 days ago - Acadia Pharmaceuticals to Present Remlifanserin Data at the 2026 Clinical Trials on Alzheimer's Disease (CTAD) Conference - Business Wire
- 9 days ago - Acadia Pharmaceuticals price target raised to $38 from $36 at Canaccord - TheFly
- 11 days ago - Acadia Pharmaceuticals Earnings Call Transcript: Q3 2026 - Transcripts
- 11 days ago - Acadia Pharmaceuticals Earnings release: Q3 2026 - Filings